0 XP   0   0   0

Vincerx Pharma Inc
Buy, Hold or Sell?

Should you buy, hold or sell Vincerx?

I guess you are interested in Vincerx Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Vincerx

Let's start. I'm going to help you getting a better view of Vincerx Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Vincerx Pharma Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Vincerx Pharma Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Vincerx Pharma Inc. The closing price on 2023-01-27 was $1.28 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Vincerx Pharma Inc Daily Candlestick Chart
Vincerx Pharma Inc Daily Candlestick Chart
Summary









1. Valuation of Vincerx




Current price per share

$1.28

2. Growth of Vincerx




Is Vincerx growing?

Current yearPrevious yearGrowGrow %
How rich?$59.7m$63.8m$17m21.0%

How much money is Vincerx making?

Current yearPrevious yearGrowGrow %
Making money-$14.5m-$10.8m-$3.7m-25.7%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Vincerx




Comparing to competitors in the Biotechnology industry




  Industry Rankings (Biotechnology)  


Richest
#641 / 1232

Most Revenue
#950 / 1232

Most Profit
#716 / 1232

Most Efficient
#348 / 1232


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Vincerx Pharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Vincerx earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Vincerx to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vincerx Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--223.6%+223.6%
TTM--281.7%+281.7%
YOY--344.8%+344.8%
5Y--450.1%+450.1%
10Y--541.0%+541.0%
1.1.2. Return on Assets

Shows how efficient Vincerx is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Vincerx to the Biotechnology industry mean.
  • -23.3% Return on Assets means that Vincerx generated $-0.23 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vincerx Pharma Inc:

  • The MRQ is -23.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -16.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-23.3%TTM-16.4%-6.9%
TTM-16.4%YOY-12.1%-4.3%
TTM-16.4%5Y-75.3%+58.9%
5Y-75.3%10Y-75.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-23.3%-9.9%-13.4%
TTM-16.4%-8.9%-7.5%
YOY-12.1%-9.3%-2.8%
5Y-75.3%-11.7%-63.6%
10Y-75.3%-12.7%-62.6%
1.1.3. Return on Equity

Shows how efficient Vincerx is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Vincerx to the Biotechnology industry mean.
  • -28.3% Return on Equity means Vincerx generated $-0.28 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vincerx Pharma Inc:

  • The MRQ is -28.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -19.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-28.3%TTM-19.5%-8.8%
TTM-19.5%YOY-17.4%-2.0%
TTM-19.5%5Y-16.4%-3.1%
5Y-16.4%10Y-16.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.3%-12.0%-16.3%
TTM-19.5%-11.5%-8.0%
YOY-17.4%-10.8%-6.6%
5Y-16.4%-14.2%-2.2%
10Y-16.4%-15.2%-1.2%

1.2. Operating Efficiency of Vincerx Pharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Vincerx is operating .

  • Measures how much profit Vincerx makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Vincerx to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vincerx Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.3%+207.3%
TTM--271.0%+271.0%
YOY--325.9%+325.9%
5Y--454.0%+454.0%
10Y--537.1%+537.1%
1.2.2. Operating Ratio

Measures how efficient Vincerx is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Vincerx Pharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.871-2.871
TTM-3.504-3.504
YOY-3.604-3.604
5Y-5.132-5.132
10Y-6.371-6.371

1.3. Liquidity of Vincerx Pharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Vincerx is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.76 means the company has $6.76 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Vincerx Pharma Inc:

  • The MRQ is 6.759. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.797. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.759TTM7.797-1.037
TTM7.797YOY3.487+4.310
TTM7.7975Y5.095+2.701
5Y5.09510Y5.0950.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.7595.117+1.642
TTM7.7975.755+2.042
YOY3.4875.854-2.367
5Y5.0956.511-1.416
10Y5.0956.222-1.127
1.3.2. Quick Ratio

Measures if Vincerx is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Vincerx to the Biotechnology industry mean.
  • A Quick Ratio of 8.66 means the company can pay off $8.66 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vincerx Pharma Inc:

  • The MRQ is 8.658. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 8.194. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.658TTM8.194+0.464
TTM8.194YOY3.042+5.151
TTM8.1945Y5.000+3.194
5Y5.00010Y5.0000.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.6584.284+4.374
TTM8.1944.664+3.530
YOY3.0424.787-1.745
5Y5.0005.218-0.218
10Y5.0005.182-0.182

1.4. Solvency of Vincerx Pharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Vincerx assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Vincerx to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.18 means that Vincerx assets are financed with 17.5% credit (debt) and the remaining percentage (100% - 17.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Vincerx Pharma Inc:

  • The MRQ is 0.175. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.154. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.175TTM0.154+0.021
TTM0.154YOY0.271-0.117
TTM0.1545Y0.390-0.236
5Y0.39010Y0.3900.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1750.278-0.103
TTM0.1540.277-0.123
YOY0.2710.306-0.035
5Y0.3900.367+0.023
10Y0.3900.403-0.013
1.4.2. Debt to Equity Ratio

Measures if Vincerx is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Vincerx to the Biotechnology industry mean.
  • A Debt to Equity ratio of 21.2% means that company has $0.21 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vincerx Pharma Inc:

  • The MRQ is 0.212. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.183. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.212TTM0.183+0.030
TTM0.183YOY0.481-0.299
TTM0.1835Y0.295-0.112
5Y0.29510Y0.2950.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2120.315-0.103
TTM0.1830.317-0.134
YOY0.4810.319+0.162
5Y0.2950.403-0.108
10Y0.2950.462-0.167

2. Market Valuation of Vincerx Pharma Inc

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Vincerx generates.

  • Above 15 is considered overpriced but always compare Vincerx to the Biotechnology industry mean.
  • A PE ratio of -1.73 means the investor is paying $-1.73 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vincerx Pharma Inc:

  • The EOD is -1.607. Company is losing money. -2
  • The MRQ is -1.732. Company is losing money. -2
  • The TTM is -10.444. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-1.607MRQ-1.732+0.126
MRQ-1.732TTM-10.444+8.711
TTM-10.444YOY-66.975+56.532
TTM-10.4445Y-39.873+29.430
5Y-39.87310Y-39.8730.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.607-8.986+7.379
MRQ-1.732-9.792+8.060
TTM-10.444-16.243+5.799
YOY-66.975-20.876-46.099
5Y-39.873-16.665-23.208
10Y-39.873-14.732-25.141
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Vincerx.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Vincerx Pharma Inc:

  • The MRQ is -1.599. Very Bad. -2
  • The TTM is -3.237. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-1.599TTM-3.237+1.638
TTM-3.237YOY-62.768+59.531
TTM-3.2375Y-33.002+29.766
5Y-33.00210Y-33.0020.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.599-0.032-1.567
TTM-3.2370.004-3.241
YOY-62.7680.016-62.784
5Y-33.0020.006-33.008
10Y-33.0020.003-33.005

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Vincerx is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.49 means the investor is paying $0.49 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Vincerx Pharma Inc:

  • The EOD is 0.454. Very good. +2
  • The MRQ is 0.490. Very good. +2
  • The TTM is 0.992. Very good. +2
Trends
Current periodCompared to+/- 
EOD0.454MRQ0.490-0.035
MRQ0.490TTM0.992-0.502
TTM0.992YOY7.734-6.742
TTM0.9925Y-72.163+73.156
5Y-72.16310Y-72.1630.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.4541.835-1.381
MRQ0.4902.006-1.516
TTM0.9922.774-1.782
YOY7.7343.453+4.281
5Y-72.1632.713-74.876
10Y-72.1632.402-74.565
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Vincerx Pharma Inc.

3.1. Institutions holding Vincerx Pharma Inc

Institutions are holding 64.596% of the shares of Vincerx Pharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-09-30Rubric Capital Management LP9.94350.1465210700000
2022-09-30SAGE RHINO CAPITAL LLC7.82550.9192165819900
2022-09-30Affinity Asset Advisors, LLC7.04480.57514927711186738.6364
2022-09-30Rock Springs Capital Management LP5.23160.0395110857029437636.1555
2022-09-30Long Focus Capital Management, LLC5.00950.14291061505815058.3168
2022-09-30TANG CAPITAL MANAGEMENT LLC4.86380.1744103063400
2022-09-30Holocene Advisors, LP3.57820.006775821400
2022-09-30Citadel Advisors Llc2.95220.000262556016330.2617
2022-09-30Vanguard Group Inc2.46420522156-57269-9.8838
2022-09-30Sabby Management LLC2.38590.880750555950000.9989
2022-09-30Schonfeld Strategic Advisors LLC2.26830.005648064618724563.8188
2022-09-30Clearline Capital LP2.1340.074645218400
2022-09-30Kingdon Capital Management LLC1.81690.067938500000
2022-09-30Point72 Asset Management, L.P.1.62730.001934482700
2022-09-30Renaissance Technologies Corp1.45680.0006308700-3822-1.223
2022-09-30Baker Bros Advisors LP1.13910.002224137900
2022-09-30Millennium Management LLC0.97980.0002207612-98986-32.2853
2022-09-30ExodusPoint Capital Management, LP0.81310.00311723027219972.1247
2022-09-30BlackRock Inc0.65490138770-3619-2.5416
2022-09-30Geode Capital Management, LLC0.6474013719100
Total 64.83683.041213738779+596935+4.3%

3.2. Funds holding Vincerx Pharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-11-30Vanguard Total Stock Mkt Idx Inv1.5768033411100
2022-09-30Vanguard Instl Ttl Stck Mkt Idx Tr1.57680334111-57269-14.6326
2022-10-31Russell Inv Tax-Managed US Mid&Sm Cap S0.97320.016320622400
2022-11-30Vanguard Extended Market Index Investor0.81660.000117304000
2022-10-31Fidelity® Extended Market Index0.35680.000375614-119-0.1571
2022-06-30BlackRock Extended Mkt Composite0.20270.000542947429470
2022-09-30BlackRock Extended Equity Market K0.1790.000537920-349-0.912
2022-11-30iShares Micro-Cap ETF0.17780.00283767700
2022-10-31Fidelity® Total Market Index0.12960.00012745500
2022-10-31Fidelity® Series Total Market Index0.076601622900
2022-09-30Northern Trust Extended Eq Market Idx0.05730.00041215100
2022-09-30NT Ext Equity Mkt Idx Fd - L0.05730.00041215100
2022-09-30NT Ext Equity Mkt Idx Fd - NL0.05530.00031170900
2022-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.04460.000394421261.3525
2022-10-31Fidelity® NASDAQ Composite Index®0.04390.0001929700
2022-09-30BlackRock Advantage SMID Cap Instl0.03820.0037809700
2022-11-30Vanguard Instl Ttl Stk Mkt Idx InstlPls0.03230684900
2022-10-31Spartan Total Market Index Pool E0.03020640600
2022-11-30Vanguard U.S. Eq Idx £ Acc0.02810595600
2022-10-31BlackRock Advantage SMID Cap V.I. Fd I0.02410.0037510300
Total 6.47720.02951372489-14664-1.1%

3.3. Insider Transactions

Insiders are holding 28.538% of the shares of Vincerx Pharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-12-14Ahmed Md HamdyBUY352800.8773760
2022-12-14Raquel E IzumiBUY287380.8868738
2022-08-24Christopher P LoweBUY184001.6528400
2022-06-27Raquel E IzumiBUY400001.4140000
2022-06-23Ahmed Md HamdyBUY242001.4138480
2022-06-09Laura I BushnellBUY150001.9119202
2021-12-22Ahmed Md HamdyBUY645010.02
2021-12-22Alexander A SeelenbergerBUY241710.34
2021-12-22Laura I BushnellBUY240210.48
2021-12-22Tom C ThomasBUY100010.23
2021-08-04Raquel E IzumiBUY100011.96
2021-06-29Andrew I. McdonaldBUY2000012.3820000
2021-06-29Tom C ThomasBUY200012.58205522

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Vincerx Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.692-0.483-30%1.192-158%0.313-321%0.313-321%
Book Value Growth--0.8030.881-9%39.226-98%20.053-96%20.053-96%
Book Value Per Share--2.8183.817-26%3.014-7%3.034-7%3.034-7%
Book Value Per Share Growth--0.8030.881-9%39.226-98%20.053-96%20.053-96%
Current Ratio--6.7597.797-13%3.487+94%5.095+33%5.095+33%
Debt To Asset Ratio--0.1750.154+14%0.271-35%0.390-55%0.390-55%
Debt To Equity Ratio--0.2120.183+16%0.481-56%0.295-28%0.295-28%
Dividend Per Share----0%-0%-0%-0%
Eps---0.797-0.687-14%-0.485-39%-0.549-31%-0.549-31%
Eps Growth--1.0840.790+37%-1.673+254%-0.441+141%-0.441+141%
Free Cash Flow Per Share---0.702-0.617-12%-0.346-51%-0.431-39%-0.431-39%
Free Cash Flow Per Share Growth--1.0640.766+39%-0.481+145%0.142+647%0.142+647%
Free Cash Flow To Equity Per Share---0.702-0.128-82%1.552-145%0.714-198%0.714-198%
Free Cash Flow To Equity Per Share Growth--1.0490.622+69%1.292-19%0.957+10%0.957+10%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--22.437--------
Intrinsic Value_10Y_min--17.721--------
Intrinsic Value_1Y_max---1.787--------
Intrinsic Value_1Y_min---1.758--------
Intrinsic Value_3Y_max---2.294--------
Intrinsic Value_3Y_min---2.252--------
Intrinsic Value_5Y_max--0.907--------
Intrinsic Value_5Y_min--0.577--------
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio0.454-8%0.4900.992-51%7.734-94%-72.163+14835%-72.163+14835%
Pe Ratio-1.607+7%-1.732-10.444+503%-66.975+3766%-39.873+2202%-39.873+2202%
Peg Ratio---1.599-3.237+102%-62.768+3826%-33.002+1964%-33.002+1964%
Price Per Share1.280-8%1.3804.223-67%17.343-92%10.962-87%10.962-87%
Price To Total Gains Ratio-1.851+7%-1.995-179.858+8914%3.171-163%-154.569+7647%-154.569+7647%
Profit Growth--1.0840.790+37%-2.214+304%-0.712+166%-0.712+166%
Quick Ratio--8.6588.194+6%3.042+185%5.000+73%5.000+73%
Return On Assets---0.233-0.164-30%-0.121-48%-0.753+223%-0.753+223%
Return On Equity---0.283-0.195-31%-0.174-38%-0.164-42%-0.164-42%
Total Gains Per Share---0.692-0.483-30%1.192-158%0.313-321%0.313-321%
Total Gains Per Share Growth--1.010-8.222+914%39.191-97%15.484-93%15.484-93%
Usd Book Value--59707000.00080890250.000-26%63865250.000-7%64293118.667-7%64293118.667-7%
Usd Book Value Change Per Share---0.692-0.483-30%1.192-158%0.313-321%0.313-321%
Usd Book Value Per Share--2.8183.817-26%3.014-7%3.034-7%3.034-7%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.797-0.687-14%-0.485-39%-0.549-31%-0.549-31%
Usd Free Cash Flow---14872000.000-13070250.000-12%-7325250.000-51%-9127972.222-39%-9127972.222-39%
Usd Free Cash Flow Per Share---0.702-0.617-12%-0.346-51%-0.431-39%-0.431-39%
Usd Free Cash Flow To Equity Per Share---0.702-0.128-82%1.552-145%0.714-198%0.714-198%
Usd Price Per Share1.280-8%1.3804.223-67%17.343-92%10.962-87%10.962-87%
Usd Profit---16879000.000-14549000.000-14%-10803000.000-36%-11565388.889-31%-11565388.889-31%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.692-0.483-30%1.192-158%0.313-321%0.313-321%
 EOD+3 -2MRQTTM+9 -25YOY+9 -255Y+11 -2310Y+11 -23

4.2. Fundamental Score

Let's check the fundamental score of Vincerx Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.607
Price to Book Ratio (EOD)Between0-10.454
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than18.658
Current Ratio (MRQ)Greater than16.759
Debt to Asset Ratio (MRQ)Less than10.175
Debt to Equity Ratio (MRQ)Less than10.212
Return on Equity (MRQ)Greater than0.15-0.283
Return on Assets (MRQ)Greater than0.05-0.233
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Vincerx Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.300
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets72,376
Total Liabilities12,669
Total Stockholder Equity59,707
 As reported
Total Liabilities 12,669
Total Stockholder Equity+ 59,707
Total Assets = 72,376

Assets

Total Assets72,376
Total Current Assets67,255
Long-term Assets67,255
Total Current Assets
Cash And Cash Equivalents 45,804
Short-term Investments 20,171
Other Current Assets 1,280
Total Current Assets  (as reported)67,255
Total Current Assets  (calculated)67,255
+/-0
Long-term Assets
Property Plant Equipment 3,479
Other Assets 1,642
Long-term Assets  (as reported)5,121
Long-term Assets  (calculated)5,121
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities9,950
Long-term Liabilities2,719
Total Stockholder Equity59,707
Total Current Liabilities
Short-term Debt 999
Accounts payable 4,393
Other Current Liabilities 4,558
Total Current Liabilities  (as reported)9,950
Total Current Liabilities  (calculated)9,950
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt2,669
Other Liabilities 50
Long-term Liabilities  (as reported)2,719
Long-term Liabilities  (calculated)2,719
+/-0
Total Stockholder Equity
Common Stock115
Retained Earnings -107,695
Accumulated Other Comprehensive Income -63
Other Stockholders Equity 167,350
Total Stockholder Equity (as reported)59,707
Total Stockholder Equity (calculated)59,707
+/-0
Other
Capital Stock2
Cash and Short Term Investments 65,975
Common Stock Shares Outstanding 21,083
Liabilities and Stockholders Equity 72,376
Net Debt -42,136
Net Invested Capital 59,707
Net Tangible Assets 59,707
Net Working Capital 57,305
Short Long Term Debt Total 3,668



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
> Total Assets 
0
0
0
475
63,192
58,000
91,137
129,425
117,676
103,881
87,744
72,376
72,37687,744103,881117,676129,42591,13758,00063,192475000
   > Total Current Assets 
0
0
0
475
63,110
54,408
86,505
123,248
111,841
98,064
82,386
67,255
67,25582,38698,064111,841123,24886,50554,40863,110475000
       Cash And Cash Equivalents 
0
0
0
36
61,792
53,355
85,623
122,796
111,459
96,486
80,857
45,804
45,80480,85796,486111,459122,79685,62353,35561,79236000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
20,171
20,17100000000000
       Other Current Assets 
0
0
0
439
214
1,053
882
452
382
1,578
1,529
1,280
1,2801,5291,5783824528821,053214439000
   > Long-term Assets 
0
0
0
0
82
3,592
4,632
6,177
5,835
5,817
5,358
5,121
5,1215,3585,8175,8356,1774,6323,592820000
       Property Plant Equipment 
0
0
0
0
0
3,372
4,445
4,419
4,182
3,950
3,716
3,479
3,4793,7163,9504,1824,4194,4453,37200000
       Other Assets 
0
0
0
82
82
220
187
1,758
1,653
1,867
1,642
1,642
1,6421,6421,8671,6531,7581872208282000
> Total Liabilities 
0
0
0
859
5,505
32,447
19,542
28,799
17,355
14,711
13,381
12,669
12,66913,38114,71117,35528,79919,54232,4475,505859000
   > Total Current Liabilities 
0
80
80
657
37,813
29,171
15,684
25,162
13,919
11,525
10,451
9,950
9,95010,45111,52513,91925,16215,68429,17137,81365780800
       Short-term Debt 
0
0
0
0
0
96
360
532
738
852
968
999
9999688527385323609600000
       Accounts payable 
0
69
69
644
491
461
1,830
2,259
2,019
3,386
5,118
4,393
4,3935,1183,3862,0192,2591,83046149164469690
       Other Current Liabilities 
0
0
0
14
32,322
28,614
13,494
22,371
13,181
7,287
4,365
4,558
4,5584,3657,28713,18122,37113,49428,61432,32214000
   > Long-term Liabilities 
0
0
0
202
0
3,276
3,858
3,637
3,436
3,186
2,930
2,719
2,7192,9303,1863,4363,6373,8583,2760202000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
50
5000000000000
> Total Stockholder Equity
0
0
0
-384
57,687
25,553
71,595
100,626
100,321
89,170
74,363
59,707
59,70774,36389,170100,321100,62671,59525,55357,687-384000
   Common Stock
0
1
1
1
1
1
1
2
6,449
2
2
115
115226,44921111110
   Retained Earnings Total Equity0000-49,499-24,975-16,66500000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
-19
-21
-6
4
-63
-634-6-21-190000000
   Capital Surplus 
0
0
0
0
0
42,043
96,569
150,142
0
0
0
0
0000150,14296,56942,04300000
   Treasury Stock000000000000
   Other Stockholders Equity 
0
-16
-16
4
0
48,493
96,569
150,142
149,864
161,569
165,173
167,350
167,350165,173161,569149,864150,14296,56948,49304-16-160



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-62,656
Operating Income-62,656-62,656
 
Operating Expense (+$)
Research Development40,081
Selling General Administrative22,575
Selling And Marketing Expenses-
Operating Expense62,65662,656
 
Net Interest Income (+$)
Interest Income-
Interest Expense-0
Net Interest Income00
 
Pretax Income (+$)
Operating Income-62,656
Net Interest Income0
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-39,306-86,006
EBIT - interestExpense = -62,656
-39,306
-39,306
Interest Expense0
Earnings Before Interest and Taxes (ebit)-62,656-39,306
Earnings Before Interest and Taxes (ebitda)-62,316
 
After tax Income (+$)
Income Before Tax-39,306
Tax Provision--
Net Income From Continuing Ops-39,306-39,306
Net Income-39,306
Net Income Applicable To Common Shares-39,306
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net23,3500
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
21W.F
3 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 21W.F.

21W.F Daily Candlestick Chart
CSPX.LSE
22 minutes ago

I found you a Golden Cross on the daily chart of CSPX.LSE.

CSPX.LSE Daily Candlestick Chart
CRL.LSE
23 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of CRL.LSE.

CRL.LSE Daily Candlestick Chart
CRH.LSE
23 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CRH.LSE.

CRH.LSE Daily Candlestick Chart
ADMIE.AT
24 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ADMIE.AT.

ADMIE.AT Daily Candlestick Chart
DUET.NASDAQ
29 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of DUET.NASDAQ.

DUET.NASDAQ Daily Candlestick Chart
POLY.XETRA
53 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of POLY.XETRA.

POLY.XETRA Daily Candlestick Chart
ENTEL.SN
56 minutes ago

I found you a Golden Cross on the daily chart of ENTEL.SN.

ENTEL.SN Daily Candlestick Chart
CENCOSUD.SN
57 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CENCOSUD.SN.

CENCOSUD.SN Daily Candlestick Chart
ANTARCHILE.SN
57 minutes ago

I found you a Death Cross on the daily chart of ANTARCHILE.SN.

ANTARCHILE.SN Daily Candlestick Chart
3BBE.XETRA
58 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of 3BBE.XETRA.

3BBE.XETRA Daily Candlestick Chart
FORUS.SN
58 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of FORUS.SN.

FORUS.SN Daily Candlestick Chart
NGA1L.MI
59 minutes ago

I found you a RSI Bullish Reversal Divergence on the daily chart of NGA1L.MI.

NGA1L.MI Daily Candlestick Chart
3CRE.XETRA
59 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 3CRE.XETRA.

3CRE.XETRA Daily Candlestick Chart
GLGI.OTCQB
1 hour ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of GLGI.OTCQB.

GLGI.OTCQB Daily Candlestick Chart
CCMCUA.SW
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CCMCUA.SW.

CCMCUA.SW Daily Candlestick Chart
AUVI.NASDAQ
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of AUVI.NASDAQ.

AUVI.NASDAQ Daily Candlestick Chart
AUUD.NASDAQ
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of AUUD.NASDAQ.

AUUD.NASDAQ Daily Candlestick Chart
AUPH.NASDAQ
1 hour ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of AUPH.NASDAQ.

AUPH.NASDAQ Daily Candlestick Chart
WIB.STU
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of WIB.STU.

WIB.STU Daily Candlestick Chart
WFSTF.PINK
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of WFSTF.PINK.

WFSTF.PINK Daily Candlestick Chart
WEDXF.PINK
1 hour ago

I found you a Golden Cross on the daily chart of WEDXF.PINK.

WEDXF.PINK Daily Candlestick Chart
WCIG.PINK
1 hour ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of WCIG.PINK.

WCIG.PINK Daily Candlestick Chart
VISA.NEO
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VISA.NEO.

VISA.NEO Daily Candlestick Chart